Concordia International Corp. Daily Stock Analysis

Daily Stock Analysis, CXRX, Concordia International Corp, priceseries

Concordia International Corp. Daily Stock Analysis
Stock Information
Open
0.19
Close
0.19
High
0.20
Low
0.19
Previous Close
0.19
Daily Price Gain
0.00
YTD High
0.89
YTD High Date
Jan 8, 2018
YTD Low
0.19
YTD Low Date
Jun 7, 2018
YTD Price Change
-0.50
YTD Gain
-72.46%
52 Week High
1.53
52 Week High Date
Jul 26, 2017
52 Week Low
0.19
52 Week Low Date
Jun 7, 2018
52 Week Price Change
-1.26
52 Week Gain
-86.90%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 1. 2017
2.09
Feb 10. 2017
2.45
7 Trading Days
17.16%
Link
LONG
May 1. 2017
1.33
May 10. 2017
1.55
7 Trading Days
16.83%
Link
Company Information
Stock Symbol
CXRX
Exchange
NasdaqGS
Company URL
http://www.concordiarx.com
Company Phone
905-842-5150
CEO
Allan Oberman
Headquarters
Ontario
Business Address
277 LAKESHORE RD. E., SUITE 302, OAKVILLE, CANADA L6J1H9
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001642271
About

Concordia International Corp. is an integrated, specialty healthcare company that focuses on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. It engages in the development of pharmaceutical products and medical devices. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in Oakville, Canada.

Description

Concordia International Corp., a specialty pharmaceutical company, owns a portfolio of branded and generic prescription products in the United States and internationally. The company's Concordia North America segment has product right sales of pharmaceutical products primarily in the United States. This segment offers a portfolio of branded and generic products, including Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; and Plaquenil for the treatment of lupus and rheumatoid arthritis. The company's Concordia International segment engages in the acquisition, manufacture, licensing, and development of off-patent prescription medicines. Its Orphan Drugs segment produces and distributes Photofrin, an orphan drug for the treatment of esophageal cancer, Barrett's esophagus, and non-small cell lung cancer. The company also provides products for the treatment of attention-deficit hyperactivity disorder, head lice infestation, and pulmonary diseases such as asthma; and control of severe or incapacitating allergic conditions such as atopic dermatitis, and seasonal and perennial allergic rhinitis. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading